Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zoe Apalla

Showing results (141-150 of 226) with videos related to

Pageof 23
Sort By:
Dermatology Practical & Conceptual|May 29, 2024
Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on SafetyZoe Apalla, Efterpi Zafiriou, Effimia Zagkliverinou, et al.
Dermatologic Therapy|December 2, 2020
Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a caseZoe Apalla, Christina Kemanetzi, Chryssoula Papageorgiou, et al.
Journal of the American Academy of Dermatology|November 26, 2013
Accuracy of dermoscopic criteria for discriminating superficial from other subtypes of basal cell carcinomaAimilios Lallas, Thrassivoulos Tzellos, Athanasios Kyrgidis, et al.
Medicina (Kaunas, Lithuania)|February 25, 2023
Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma SubtypesElisa Camela, Paula Ilut Anca, Konstantinos Lallas, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 19, 2025
Clarifying follow-up duration, risk features and limitations in longitudinal melanonychia monitoringElvira Moscarella, Gabriella Brancaccio, Zoe Apalla, et al.
Clinical and Experimental Dermatology|October 14, 2023
Dermatoscopic shiny white structures in benign cutaneous tumoursAimilios Lallas, Claudio Toloza, Juan Pablo Morales, et al.
Journal of the American Academy of Dermatology|June 9, 2026
Response to Zou et al., " Comment on "Clinical features, treatment outcomes, and immunologic profile of immune checkpoint inhibitor-associated bullous pemphigoid: a retrospective multicenter cohort study""Vasiliki Nikolaou, Ioannis-Alexios Koumprentziotis, Maria Gerochristou, et al.
Journal of the American Academy of Dermatology|September 24, 2022
Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective studyAzael Freites-Martinez, Vasiliki Nikolaou, Konstantinos Lallas, et al.
Dermatology (Basel, Switzerland)|June 7, 2021
Dermoscopic Predictors of Benignity and Malignancy in Equivocal Lesions Predominated by Blue ColorKonstantinos Lallas, Montserrat Arceu, Guisella Martinez, et al.
Journal of the American Academy of Dermatology|February 25, 2026
Clinical features, treatment outcomes, and immunologic profile of immune checkpoint inhibitor-associated bullous pemphigoid: a retrospective multicenter cohort studyVasiliki Nikolaou, Ioannis-Alexios Koumprentziotis, Maria Gerochristou, et al.
Pageof 23

Showing results (141-150 of 226) with videos related to

Sort By:
Pageof 23
Dermatology Practical & Conceptual|May 29, 2024
Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on SafetyZoe Apalla, Efterpi Zafiriou, Effimia Zagkliverinou, et al.
Dermatologic Therapy|December 2, 2020
Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a caseZoe Apalla, Christina Kemanetzi, Chryssoula Papageorgiou, et al.
Journal of the American Academy of Dermatology|November 26, 2013
Accuracy of dermoscopic criteria for discriminating superficial from other subtypes of basal cell carcinomaAimilios Lallas, Thrassivoulos Tzellos, Athanasios Kyrgidis, et al.
Medicina (Kaunas, Lithuania)|February 25, 2023
Dermoscopic Clues of Histopathologically Aggressive Basal Cell Carcinoma SubtypesElisa Camela, Paula Ilut Anca, Konstantinos Lallas, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 19, 2025
Clarifying follow-up duration, risk features and limitations in longitudinal melanonychia monitoringElvira Moscarella, Gabriella Brancaccio, Zoe Apalla, et al.
Clinical and Experimental Dermatology|October 14, 2023
Dermatoscopic shiny white structures in benign cutaneous tumoursAimilios Lallas, Claudio Toloza, Juan Pablo Morales, et al.
Journal of the American Academy of Dermatology|June 9, 2026
Response to Zou et al., " Comment on "Clinical features, treatment outcomes, and immunologic profile of immune checkpoint inhibitor-associated bullous pemphigoid: a retrospective multicenter cohort study""Vasiliki Nikolaou, Ioannis-Alexios Koumprentziotis, Maria Gerochristou, et al.
Journal of the American Academy of Dermatology|September 24, 2022
Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective studyAzael Freites-Martinez, Vasiliki Nikolaou, Konstantinos Lallas, et al.
Dermatology (Basel, Switzerland)|June 7, 2021
Dermoscopic Predictors of Benignity and Malignancy in Equivocal Lesions Predominated by Blue ColorKonstantinos Lallas, Montserrat Arceu, Guisella Martinez, et al.
Journal of the American Academy of Dermatology|February 25, 2026
Clinical features, treatment outcomes, and immunologic profile of immune checkpoint inhibitor-associated bullous pemphigoid: a retrospective multicenter cohort studyVasiliki Nikolaou, Ioannis-Alexios Koumprentziotis, Maria Gerochristou, et al.
Pageof 23